Novel psychoactive substances: A review;Nouveaux produits de synthèse: Revue des données actuelles

Presse Medicale

Volumn 44, Issue 4, 2015, Pages 383-391

  Karila, Laurent ^a   Megarbane, Bruno ^b,c   Chevillard, Lucie ^b,c   Benturquia, Nadia ^b,c   Laplanche, Jean Louis ^b,c   Lejoyeux, Michel ^c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UMR S 1144   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT; ALKALOID; CANNABINOID; CATHINONE;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; SUBSTANCE-RELATED DISORDERS; SYNTHESIS;

ALKALOIDS; CANNABINOIDS; HUMANS; PSYCHOTROPIC DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84928207282     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.09.020     Document Type: Article

References (54)

1. Lahaie E., Martinez M., Cadet-Taïrou A. Nouveaux produits de synthèse et Internet. OFDT - Tendances 2013, 84:1-8.
2. European Monitoring Center for Drugs and Drug Addiction (EMCDDA) 2012annual report on the state of the drugs problem in Europe 2012, Accès au site le 20/12/2014. http://www.emcdda.europa.eu/publications/annual-report/2012.
3. EMCDDA European drug report 2014: trends and developments 2014, Accès au site le 20/12/2014. http://www.emcdda.europa.eu/publications/edr/trends-developments/2014.
4. Fornis Espinosa I., Vidal Gine C., Caudevilla Galligo F., Ventura Vilamala M. New synthetic drugs: legal highs in Spain (2010-2012). Med Clin (Barc) 2013, 140:189-190.
5. Kapka-Skrzypczak L., Kulpa P., Sawicki K., Cyranka M., Wojtyla A., Kruszewski M. Legal highs - legal aspects and legislative solutions. Ann Agric Environ Med 2011, 18:304-309.
6. Karila L., Petit A., Cottencin O., Coscas S., Reynaud M. Synthetic drugs: the new low-cost landscape of drugs. Rev Prat 2012, 62:664-666.
7. Archer J.R., Dargan P.I., Lee H.M., Hudson S., Wood D.M. Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances. Clin Toxicol 2014, 52:160-165.
8. Wiessing L. European drugs agency highlights trends in drug use and problems affecting drug users. Euro Surveill 2005, 10. E051215 3.
9. Deluca P., Davey Z., Corazza O., Di Furia L., Farre M., Flesland L.H., et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:221-226.
10. Wood D.M., Heyerdahl F., Yates C.B., Dines A.M., Giraudon I., Hovda K.E., et al. The European Drug Emergencies Network (EuroDEN). Clin Toxicol (Phila) 2014, 52:239-241.
11. Ministère des Affaires sociale et de la santé Arrêté du 27juillet 2012modifiant les arrêtés du 22février 1990fixant la liste des substances classées comme stupéfiants et la liste des substances psychotropes. JORF 2012, 0178. 2aoÛt 2012.
12. OEDT Rapport Européen sur les drogues 2013: tendances et évolution 2013, Office des publications de l'Union Européenne, Luxembourg.
13. Debruyne D., Courne M.A., Le Boisselier R., Djezzar S., Gerardin M., Boucher A., et al. Mephedrone: a designer drug of recent use in France. Therapie 2010, 65:519-524.
14. Johnson L.A., Johnson R.L., Portier R.B. Current "legal highs". J Emerg Med 2013, 44:1108-1115.
15. EMCDDA 2011Annual report on the state of the drugs problem in Europe 2011, Accès au site le 20/12/2014. http://www.emcdda.europa.eu/publications/annual-report/2011.
16. Dresen S., Ferreiros N., Putz M., Westphal F., Zimmermann R., Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010, 45:1186-1194.
17. Wells D.L., Ott C.A. The "new" marijuana. Ann Pharmacother 2011, 45:414-417.
18. Harris C.R., Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013, 44:360-366.
19. Auwarter V., Dresen S., Weinmann W., Muller M., Putz M., Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009, 44:832-837.
20. Moller I., Wintermeyer A., Bender K., Jubner M., Thomas A., Krug O., et al. Screening for the synthetic cannabinoid JWH-018and its major metabolites in human doping controls. Drug Test Anal 2011, 3:609-620.
21. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011, 3:552-559.
22. Rosenbaum C.D., Carreiro S.P., Babu K.M. Here today, gone tomorrow. and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012, 8:15-32.
23. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013, 168:458-470.
24. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012, 8:33-42.
25. Cameron K., Kolanos R., Verkariya R., De Felice L., Glennon R.A. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts", produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 2013, 227:493-499.
26. Cottencin O., Rolland B., Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Current pharmaceutical design 2014, 20:4106-4111.
27. AIDES/Sidaction/AMG/Inserm SLAM, première enquête qualitative en France 2013, Association AIDES, Paris.
28. Csak R., Demetrovics Z., Racz J. Transition to injecting 3,4-methylene-dioxypyrovalerone (MDPV) among needle exchange program participants in Hungary. J Psychopharmacol 2013, 27:559-563.
29. Van Hout M.C., Bingham T. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy 2012, 23:188-197.
30. Joksovic P., Mellos N., van Wattum P.J., Chiles C. "Bath salts"-induced psychosis and serotonin toxicity. J Clin Psychiatry 2012, 73:1125.
31. Karila L., Reynaud M. Mephedrone: a designer drug legally available on the Web. Presse Med 2010, 39:834-835.
32. Watterson L.R., Kufahl P.R., Nemirovsky N.E., Sewalia K., Grabenauer M., Thomas B.F., et al. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 2014, 19:165-174.
33. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011, 49:499-505.
34. Miotto K., Striebel J., Cho A.K., Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 2013, 132:1-12.
35. Ross E.A., Reisfield G.M., Watson M.C., Chronister C.W., Goldberger B.A. Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone. Am J Med 2012, 125:854-858.
36. Rasimas J.J. "Bath salts" and the return of serotonin syndrome. J Clin Psychiatry 2012, 73:1126-1127.
37. Kovacs K., Toth A.R., Kereszty E.M. A new designer drug: methylone related death. Orv Hetil 2012, 153:271-276.
38. Prozialeck W.C., Jivan J.K., Andurkar S.V. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 2012, 112:792-799.
39. Arndt T., Claussen U., Gussregen B., Schrofel S., Sturzer B., Werle A., et al. Kratom alkaloids and O-desmethyltramadol in urine of a "Krypton" herbal mixture consumer. Forensic Sci Int 2011, 208:47-52.
40. Maurer H.H. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit 2010, 32:544-549.
41. Hassan Z., Muzaimi M., Navaratnam V., Yusoff N.H., Suhaimi F.W., Vadivelu R., et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev 2013, 37:138-151.
42. Logan B., Jillian K., Goldfogel G., Frost M., Sandstrom G., Wickham D. Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic Sci 2012, 57:1388-1394.
43. Hennies H.H., Friderichs E., Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988, 38:877-880.
44. Kronstrand R., Roman M., Thelander G., Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 2011, 35:242-247.
45. Hofer K.E., Grager B., Muller D.M., Rauber-Luthy C., Kupferschmidt H., Rentsch K.M., et al. Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med 2012, 60:97-99.
46. Corazza O., Schifano F., Simonato P., Fergus S., Assi S., Stair J., et al. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol 2012, 27:145-149.
47. Corazza O., Assi S., Schifano F. From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 2013, 19:454-460.
48. Dargan P.I., Tang H.C., Liang W., Wood D.M., Yew D.T. Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol (Phila) 2014, 52:176-180.
49. Elie M.P., Elie L.E., Baron M.G. Keeping pace with NPS releases: fast GC-MS screening of legal high products. Drug Test Anal 2013, 5:281-290.
50. Sainsbury P.D., Kicman A.T., Archer R.P., King L.A., Braithwaite R.A. Aminoindanes - the next wave of 'legal highs'?. Drug Test Anal 2011, 3:479-482.
51. Elie L., Baron M., Croxton R., Elie M. Microcrystalline identification of selected designer drugs. Forensic Sci Int 2012, 214:182-188.
52. Iversen L., Gibbons S., Treble R., Setola V., Huang X., Roth B. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 2013, 700:147-151.
53. Welter J., Meyer M.R., Wolf E.U., Weinmann W., Kavanagh P., Maurer H.H. 2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem 2013, 405:3125-3135.
54. Gibbons S. 'Legal highs' - novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol (Phila) 2012, 50:15-24.